Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

BACKGROUND: Patients with recurrent/metastatic endometrial cancer that progresses after chemotherapy have limited treatment options and poor outcomes. Preclinical data suggest the oral mammalian target of rapamycin inhibitor everolimus may provide clinical benefit in these patients. METHODS: In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray-Coquard, I, Favier, L, Weber, B, Roemer-Becuwe, C, Bougnoux, P, Fabbro, M, Floquet, A, Joly, F, Plantade, A, Paraiso, D, Pujade-Lauraine, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658508/
https://www.ncbi.nlm.nih.gov/pubmed/23612453
http://dx.doi.org/10.1038/bjc.2013.183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658508/
https://www.ncbi.nlm.nih.gov/pubmed/23612453
http://dx.doi.org/10.1038/bjc.2013.183

Ejemplares similares